Clinical Trials Logo

Clinical Trial Summary

This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.


Clinical Trial Description

The standard treatment for locally advanced colon cancer is surgery followed by adjuvant chemotherapy containing oxaliplatin. The MOSAIC and 16968 studies have shown that approximately 30% of patients experience recurrence and metastasis within 6-7 years after surgery. Neoadjuvant chemotherapy may improve the prognosis of patients with malignant tumors. The significant tumor shrinkage after neoadjuvant therapy indicates a greater likelihood of long-term survival for patients. The OPTICAL and FoxTROT studies have shown that approximately 35% of patients are resistant to oxaliplatin-containing neoadjuvant chemotherapy, with a pCR rate of less than 10% and uncertain survival improvement. In addition, immunotherapy has poor efficacy for microsatellite stable (MSS) patients. Therefore, it is necessary to explore new and effective neoadjuvant treatment modalities for tumor regression. The study will screen for individuals who are sensitive to oxaliplatin-containing regimens through induction chemotherapy. Immunogenic cell death will be enhanced by oxaliplatin-induced immunogenicity and combined with anti-programmed cell death ligand 1 (PD-L1) monoclonal antibodies for neoadjuvant therapy. In the context of cancer, the role of the intestinal microbiome in mediating immune activation induced by chemotherapy drugs has been demonstrated. Clostridium butyricum will be introduced as an adjuvant to explore the possibility of further increasing the significant response rate of neoadjuvant therapy. The study will first conduct 2 cycles of Capox induction chemotherapy to screen for patients sensitive to chemotherapy. Patients will be randomized into three cohorts: one chemotherapy standard control cohort (continuing Capox chemotherapy for 2 cycles) and two enhancement design cohorts (Capox chemotherapy + Anti-PD-L1 monoclonal antibody for 2 cycles/Capox chemotherapy + Anti-PD-L1 monoclonal antibody + Clostridium butyricum for 2 cycles), followed by CME surgery. The study's primary endpoint is the proportion of Tumor regression grade(TRG)0/1 in the pathological specimens of surgically resected tumors. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05914389
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Li Jun, MD
Phone +86 13777878061
Email 2307016@zju.edu.cn
Status Recruiting
Phase Phase 2
Start date August 2023
Completion date August 2030

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Terminated NCT04555135 - A Clinical Study To Measure The Effect Of Use Of Artificial Intelligence (AI) Enabled Computer Aided Detection (CADe) Assistance Software In Detecting Colon Polyps During Standard Colonoscopy Procedures N/A
Terminated NCT00249301 - A Study of MLN8054 in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05279612 - Effect Analysis of Neoadjuvant Chemoradiotherapy Combined With Surgery in Laparoscope for Advanced Colon Cancer
Active, not recruiting NCT04369053 - Prevention of Colorectal Cancer Through Multiomics Blood Testing
Recruiting NCT05411783 - Low Tie Versus High Tie of the Inferior Mesenteric Vein During Colorectal Cancer Surgery: A Randomized Clinical Trial N/A
Recruiting NCT05345613 - Tranexamic Acid During Colonic Endoscopic Resection Procedures Phase 4
Recruiting NCT03803891 - Endoscopic Full-Thickness Resection In Colon
Completed NCT04799080 - Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function
Recruiting NCT05034692 - Application of Overlap Method to Digestive Tract Reconstruction of Totally Laparoscopic Left Colectomy N/A
Recruiting NCT04920149 - Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome Phase 2
Not yet recruiting NCT00295035 - Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer Phase 3
Recruiting NCT03065257 - Endoscopic Resection Multicenter Registry N/A
Recruiting NCT03198338 - Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit N/A
Completed NCT05497726 - Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW N/A
Completed NCT03723720 - Calculating of Correlations Between ADR, PDR, MAP
Completed NCT03730441 - Correlation Between ADR of Screening and All Colonoscopies
Recruiting NCT05446558 - Long-term Results in Intracorporeal Versus Extracorporeal Anastomosis in Laparoscopic Right Colectomy N/A
Recruiting NCT03458689 - Quadratus Lumborum Block Versus Transversus Abdominis Plane Block in Patients Undergoing Left Hemicolectomy N/A
Completed NCT03719573 - Geriatric Assessment and Intervention in Older Patients Undergoing Surgery for Colorectal Cancer N/A